Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Freedom Meditech
A six second scan of the eye detects autofluorescence of the crystalline lens.
SAN DIEGO, Oct. 30, 2013 /PRNewswire/ -- Freedom Meditech, Inc. has announced that the company has been invited to present a live demonstration of the ClearPath DS-120™ at the 13th Annual Diabetes Technology Meeting, the premier event in the United States for showcasing latest technological advances for people with diabetes. Cleared by the U.S. Food and Drug Administration (FDA) in January 2013, the ClearPath DS-120 is a first-in-class, non-invasive tool designed to quickly and accurately measure autofluorescence through a six second scan of the crystalline lens of the eye. A significant number of independent peer-reviewed studies have suggested that elevated lens autofluorescence may be an early indicator of the presence of diabetes.
"The Diabetes Technology Meeting provides an opportunity to educate diabetes professionals about the clinical value of non-invasive lens autofluorescence and the associated market size estimated at $4 billion worldwide," said Craig Misrach, CEO of Freedom Meditech. "ClearPath can facilitate the co-management of patients between physicians and eye care professionals, which in turn, can maximize earlier detection and monitoring of patients at risk of developing complications related to diabetes."
The meeting will feature more than 500 clinicians and scientists from 24 countries and will focus on applying science and technology to prevent and treat diabetes. The goal of the meeting is to facilitate the creation of new and cost-effective tools between diabetes thought leaders and developers.
"The most cutting-edge inventions in the global diabetes marketplace are featured at the Diabetes Technology Meeting and it's only appropriate that non-invasive lens autofluorescence be included," said David C. Klonoff, M.D., F.A.C.P., chair of the Diabetes Technology Meeting. "Technologies that enable the early detection of diabetes with a footprint capable of reaching a wider patient population are essential to disease intervention and reversing the direction of the Type 2 diabetes epidemic."
Freedom Meditech will conduct a live demonstration of the ClearPath at 2:10 p.m. on November 2, 2013 at the Diabetes Technology Meeting taking place at the Hyatt Regency San Francisco Airport in Burlingame, California.
About ClearPath DS-120™
The ClearPath DS-120™ Lens Fluorescence Biomicroscope is cleared by FDA as a tool for the measurement of autofluorescence by scanning the crystalline lens of the eye with a blue light. In independent scientific studies published in peer-reviewed journals, elevated autofluorescence measurements have been linked to high levels of advanced glycosylated end products which accumulate as a result of the aging process and the presence of systemic disease.
The ClearPath scan is pain free, takes just six seconds and produces an immediate, quantitative result available to the patent and healthcare provider. Unlike some eye exams, the scan does not require dilation. The ClearPath is completely non-invasive and does not require a blood draw to produce a result. The device has a small footprint, sits on a table top, and employs an easy to use touch screen display that can be wirelessly linked to a practitioner's electronic medical record system.
About Freedom Meditech
Freedom Meditech, Inc. is a medical device company focused on the commercialization of novel ophthalmic technologies for the detection of disease and management of patient health. The company has received FDA clearance for its first product, ClearPath DS-120™, a non-invasive tool for the measurement of autofluorescence in the eye. I-SugarX is the company's second product currently in development as a non-invasive ophthalmic glucose monitor that measures glucose levels in the eye for people with diabetes. The company maintains corporate and engineering operations in San Diego, CA with supporting research and development activities throughout the state of Ohio. For more information, visit www.freedom-meditech.com or find us on Twitter, Facebook and LinkedIn.
©2012 PR Newswire. All Rights Reserved.